Renascience Inc.
TTSE:4889990.00
JPY
-31.00
(-3.04%)
Renascience Inc.
TSE:4889
(Tokyo Stock Exchange)
Recent
price
990.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.- Similar Companies
- Business
- Renascience Inc. (4889.T) develops and commercializes pharmaceuticals and medical devices targeting non-communicable aging-related diseases including cancer, diabetes, respiratory diseases and cardiovascular diseases, as well as women's and children's health conditions; its pipeline features RS5614 (TM-5614), a PAI-1 inhibitor in Phase 3 trials for chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, cutaneous angiosarcoma, interstitial lung disease associated with systemic scleroderma and FGF23-related hypophosphatemic rickets; RS5441, a PAI-1 inhibitor in Phase 1 for dermatological diseases; RS8001 (pyridoxamine), a water-soluble vitamin in Phase 2 for premenstrual syndrome, premenstrual dysphoric mood disorder, autism spectrum disorder and menopausal disorder; RS9001, an approved disposable ultrafine endoscope; and artificial intelligence-based solutions for diabetes treatment, maintenance hemodialysis and diagnostics. Founded in 2000 and headquartered in Sendai City, Miyagi Prefecture, Japan, following its October 2024 relocation from Tokyo, the company operates primarily in Japan through open innovation labs such as TREx at Tohoku University and HiREx at Hiroshima University. Recent developments include regulatory designation of its malignant melanoma drug as a rare disease treatment in September 2024; a joint development agreement with Taipei Medical University (TMU)-Biotech Co., Ltd. in November 2024; an agreement in January 2025 to host Northwestern University's Potocsnak Longevity Institute at TREx; initiation of Phase 3 trials for RS5614 in malignant melanoma in February 2025; and selection as a Top 40 winner in the XPRIZE Healthspan competition in May 2025.